Prelude Therapeutics Inc (PRLD)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Prelude Therapeutics Inc reported revenue of $12.14M, up 73.4% from the prior year. The company ran a net loss, with a net margin of -819.6%. It held $141.31M in total assets against $72.68M in total liabilities.
Key ratios (FY2025)
-861.3%
Operating margin
-819.6%
Net margin
-145.0%
Return on equity
+73.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.14M | $7.00M | — | — | — | — | — | — |
| Operating Income | -$104.57M | -$139.71M | -$132.28M | -$123.54M | -$113.73M | -$58.76M | -$28.11M | — |
| Net Income | -$99.50M | -$127.17M | -$121.83M | -$115.44M | -$111.69M | -$56.93M | -$27.57M | — |
| EPS (Diluted) | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 | — | — | — |
| Total Assets | $141.31M | $175.51M | $277.67M | $220.50M | $305.10M | $223.59M | $21.87M | — |
| Total Liabilities | $72.68M | $44.06M | $40.58M | $25.06M | $19.20M | $11.41M | $4.84M | — |
| Shareholders' Equity | $68.64M | $131.46M | $237.09M | $195.44M | $285.90M | $212.18M | -$49.41M | -$22.69M |
| Cash & Equivalents | $35.26M | $12.47M | $25.29M | $30.61M | $31.83M | $218.31M | $18.88M | — |
| Operating Cash Flow | -$56.30M | -$102.89M | -$107.06M | -$83.73M | -$83.53M | -$46.18M | -$25.66M | — |
| Capital Expenditures | $67.0K | $764.0K | $3.51M | $3.02M | $2.32M | $621.0K | $780.0K | — |
| Shares Outstanding | 76.96M | 75.81M | 60.36M | 47.37M | 46.05M | — | — | — |